Biotech meets silicon—Medra just pocketed $52 million to turbocharge drug discovery using AI-powered robotics. The funding round signals growing investor appetite for automation in pharmaceutical research, where machine learning models can screen thousands of compound combinations in the time it'd take human researchers to test a handful. While traditional drug development crawls through decade-long timelines, Medra's robotic platform promises to slash that by running parallel experiments 24/7. It's the kind of efficiency play that's got both pharma giants and venture funds paying attention. As AI continues eating into every industry vertical, healthcare's becoming the next major battleground—and whoever cracks the code on faster, cheaper drug pipelines stands to reshape a trillion-dollar market.